Leap Therapeutics (LPTX) Stock Price, News & Analysis

Company Overview

Leap Therapeutics, Inc. (NASDAQ: LPTX) is a clinical-stage biotechnology company focused on the discovery and development of targeted therapies and immuno-oncology treatments for patients with cancer. The company advances candidates through preclinical and clinical development with the goal of addressing unmet needs in solid tumors by modulating tumor biology and antitumor immune responses.

Leap’s research and development strategy emphasizes biologic therapeutic agents and combination approaches intended to enhance efficacy in difficult-to-treat cancers. The company pursues clinical programs designed to generate proof-of-concept data and to support regulatory interactions, and it seeks strategic collaborations to accelerate development and broaden access to its investigational therapies.

As a development-stage company, Leap conducts clinical trials and engages with academic and industry partners to progress its pipeline. Public filings and company communications provide additional details on specific programs, trial designs and partnership arrangements for investors and other stakeholders interested in the company’s development trajectory.

Key Stats

• Today's Range: N/A
• 50-Day Range: $2.05 to $2.05
• 52-Week Range: N/A
• Volume: 760.56 million shs
• Average Volume: 40.67 million shs
• Market Capitalization: $84.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

LPTX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Leap Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Leap Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), OPKO Health (OPK).

Company Calendar

• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: N/A
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LPTX
• CIK: 1509745
• Web: N/A
• Phone: (617) 252-4343
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$67.56 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -247.44%
• Return on Assets: -146.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.34
• Quick Ratio: 1.34

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.91 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 41,440,000
• Free Float: 39,658,000
• Market Cap: $84.95 million
• Optionable: N/A
• Beta: -0.06